KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Non-Current Assets (2016 - 2026)

Bio-Rad Laboratories has reported Non-Current Assets over the past 18 years, most recently at $6.8 billion for Q1 2026.

  • Quarterly Non-Current Assets rose 350.98% to $6.8 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $28.8 billion through Mar 2026, up 1248.01% year-over-year, with the annual reading at $7.7 billion for FY2025, 21.1% up from the prior year.
  • Non-Current Assets was $6.8 billion for Q1 2026 at Bio-Rad Laboratories, down from $7.7 billion in the prior quarter.
  • Over five years, Non-Current Assets peaked at $11.1 billion in Q1 2022 and troughed at -$3.2 billion in Q4 2022.
  • The 5-year median for Non-Current Assets is $6.9 billion (2025), against an average of $4.4 billion.
  • Year-over-year, Non-Current Assets tumbled 134.92% in 2024 and then soared 350.98% in 2026.
  • A 5-year view of Non-Current Assets shows it stood at -$3.2 billion in 2022, then grew by 3.46% to -$3.0 billion in 2023, then surged by 307.8% to $6.3 billion in 2024, then increased by 21.1% to $7.7 billion in 2025, then decreased by 10.72% to $6.8 billion in 2026.
  • Per Business Quant, the three most recent readings for BIO's Non-Current Assets are $6.8 billion (Q1 2026), $7.7 billion (Q4 2025), and $6.9 billion (Q3 2025).